
On October 31, 2Firsts reported that the U.S. Food and Drug Administration (FDA) issued warning letters to nine online retailers and one manufacturer, accusing them of selling unauthorized smart e-cigarettes (click to read the article). According to 2Firsts' analysis of the FDA warning letters, six e-cigarette brands were involved: FUME, Craftbox, North Vape, Posh, Halo Vapor, and Swype.
2Firsts noted that in the ten FDA warning letters, the agency described how "these products' labels or advertising may appeal to youth by imitating smartphones or other smart technologies" and "may attract teenagers by resembling gaming products," labeling these products as "highly concerning".

Below is a list compiled by 2Firsts from the FDA warning letters, detailing the brands and products mentioned:
FUME
The product cited in the warning letter is:
- WeFume Vape 30K Puffs – cited 3 times

Craftbox
The products mentioned in the warning letters are:
- Craftbox V-Touch 30k Puff Smart Disposable Vape – cited 4 times
- Craftbox V-Play 20K Puffs Disposable Vape – cited 5 times
- Craftbox V-Touch 30,000 Puffs Phone Call Vape Disposable– cited 1 time

North Vape
The products cited in the warning letter are:
- North South Connect 35K Puffs Phone Disposable Vape – cited 2 times
- South Connect 35K Disposable Vape Bluetooth 900mAh – cited 1 time


Posh
The products cited in the warning letter are:
- Posh Xtron 30000 Disposable Vape – cited 1 time
- Posh Pro Max 30000 – cited 1 time

Halo Vapor
The product cited in the warning letter is:
- Halo Vapor Synix 30K – cited 2 times

Swype
The product cited in the warning letter is:
- Swype 30K Disposable Vape – cited 1 time

According to information disclosed by the FDA, when the agency identifies what it considers to be serious violations of federal requirements, it notifies the relevant parties.
This notification typically takes the form of a warning letter, which highlights issues such as poor manufacturing practices, problematic product efficacy claims, or incorrect usage instructions. The letter provides companies or individuals with an opportunity to address the FDA’s concerns, requiring a response within a specified timeframe. This response may include a corrective plan, after which the FDA will conduct follow-up inspections to ensure that corrective measures are sufficient.
If a company or individual disagrees with the FDA's assessment, they have the opportunity to present their reasons and supporting information to the FDA. These communications and other actions between the FDA and the letter recipient may alter the regulatory status of the issues discussed in the letter.
As of October 30, 2024, the FDA has authorized 34 e-cigarette products and devices. The agency maintains a printable one-page flyer listing all authorized e-cigarette products, which retailers can reference to verify which products may be legally marketed and sold in the United States. Entities manufacturing, importing, selling, or distributing e-cigarettes without the necessary premarket authorization will face enforcement risks.
Notice
1. This article is provided exclusively for professional research purposes related to industry, technology and policy. Any reference to brands or products is made solely for the purpose of objective description and does not constitute an endorsement, recommendation, or promotion of any brand or product.
2. The use of nicotine products, including but not limited to cigarettes, e-cigarettes, and heated tobacco products, is associated with significant health risks. Users are required to comply with all relevant laws and regulations in their respective jurisdictions.
3. This article is strictly restricted from being accessed or viewed by individuals under the legal age.
Copyright
This article is either an original work by 2Firsts or a reproduction from third-party sources with the original source clearly indicated. The copyright and usage rights of this article belong to 2Firsts or the original source. Unauthorized reproduction, distribution, or any other unauthorized use of this article by any entity or individual is strictly prohibited. Violators will be held legally responsible. For copyright-related matters, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have utilized AI to enhance translation and editing efficiency. However, due to technical limitations, errors may occur. Readers are advised to refer to the sources provided for more accurate information.
This article should not be used as a basis for any investment decisions or advice, and 2Firsts assumes no direct or indirect liability for any errors in the content.